<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615627</url>
  </required_header>
  <id_info>
    <org_study_id>JGH-12-058</org_study_id>
    <nct_id>NCT01615627</nct_id>
  </id_info>
  <brief_title>Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain</brief_title>
  <official_title>Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test whether hypotonic (diluted) remodulin solution causes less pain
      than the eutonic (undiluted) solution supplied by the manufacturer.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment
  </why_stopped>
  <start_date type="Actual">July 1, 2012</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Pain Diary</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>McGill Pain Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAMPHOR quality of life questionnaire</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Hypotonic Treprostinil Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypotonic Treprostinil Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eutonic Treprostinil Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eutonic Treprostinil Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HypotonicTreprostinil Solution</intervention_name>
    <description>Hypotonic Treprostinil Solution</description>
    <arm_group_label>Hypotonic Treprostinil Solution</arm_group_label>
    <other_name>Hypotonic Remodulin Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eutonic Treprostinil Solution</intervention_name>
    <description>Eutonic Treprostinil Solution</description>
    <arm_group_label>Eutonic Treprostinil Solution</arm_group_label>
    <other_name>Eutonic Remodulin Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PAH by standard criteria

          -  Treatment with subcutaneous remodulin infusion for at least 3 months, with stable dose
             for 1 month

          -  Pain at infusion site (defined as &gt; 8 on McGill Pain Questionnaire)

        Exclusion Criteria:

          -  Known pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Langleben, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>February 29, 2020</last_update_submitted>
  <last_update_submitted_qc>February 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr David Langleben</investigator_full_name>
    <investigator_title>Chair, Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>Subcutaneous Treprostinil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

